Alpha Teknova, Inc. (TKNO) Q2 2025 Earnings Call Transcript
Total Revenue $10.3 million in Q2 2025, a 7% increase from $9.6 million in Q2 2024. The growth was driven by strength in sales of catalog products, which grew in the low double digits.
Lab Essentials Revenue $7.8 million in Q2 2025, a 2% increase from $7.6 million in Q2 2024. The increase was due to an increased number of customers, partially offset by slightly lower average revenue per customer.
Clinical Solutions Revenue $2.1 million in Q2 2025, a 32% increase from $1.6 million in Q2 2024. The increase was due to an increased number of customers, partially offset by lower average revenue per customer.
Gross Profit $4.0 million in Q2 2025, up from $2.8 million in Q2 2024. The increase was driven by manufacturing efficiency gains and higher revenue.
Gross Margin 38.7% in Q2 2025, up from 29.2% in Q2 2024. The improvement was due to manufacturing efficiency gains and higher revenue.
Operating Expenses $7.4 million in Q2 2025, down from $7.9 million in Q2 2024. The decrease was driven primarily by reduced spending on insurance and facility costs.
Net Loss $3.6 million in Q2 2025, compared to $5.4 million in Q2 2024. The improvement was due to higher revenue and reduced operating expenses.
Adjusted EBITDA Negative $0.8 million in Q2 2025, compared to negative $2.6 million in Q2 2024. The improvement was due to higher revenue and manufacturing efficiency gains.
Capital Expenditures $0.2 million in Q2 2025, compared to $0.1 million in Q2 2024. The increase was due to planned investments.
Free Cash Flow Negative $2.3 million in Q2 2025, compared to negative $3.0 million in Q2 2024. The improvement was due to higher revenue and reduced operating expenses.
Trade with 70% Backtested Accuracy
Analyst Views on TKNO
About TKNO
About the author
Alpha Teknova (TKNO) Third Quarter 2025 Earnings Call Transcript
- Author's Perspective: The views and opinions presented are solely those of the author.
- No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
IMRX Rises on Pancreatic Cancer Findings, PEPG Achieves DM1 Splicing Correction Milestone, CLPT Under Observation
Biotech Stock Performance: Several biotech stocks, including PepGen and Immuneering, experienced significant gains due to positive clinical trial results, with PepGen's stock soaring 36% during regular trading and an additional 134% in after-hours trading following promising data for its myotonic dystrophy treatment.
Clinical Trial Updates: Immuneering reported an impressive overall survival rate of 86% in its pancreatic cancer trial, while other companies like Clearmind Medicine and Jasper Therapeutics also saw stock increases based on ongoing clinical evaluations and positive preliminary results.
Market Developments: ClearPoint Neuro's stock surged over 58% after receiving FDA clearance for its laser therapy system, expanding its market potential, while Neuphoria Therapeutics anticipates topline results from its social anxiety disorder trial in early Q4 2025.
Investor Interest: The overall investor interest in biotech stocks is reflected in the significant price movements of various companies, driven by clinical trial advancements and strategic opportunities, indicating a robust market for biotech innovations.
Experts Forecast Potential 840% Surge for These 2 'Strong Buy' Penny Stocks
Penny Stocks vs. Mega-Cap Stocks: While large companies like Nvidia dominate the stock market, penny stocks (priced below $5) offer significant growth potential, with the possibility of triple-digit percentage gains, though investors must be cautious due to inherent risks.
Highlighted Penny Stocks: Two penny stocks, Protara Therapeutics (TARA) and Alpha Teknova (TKNO), have received strong buy ratings from analysts, with TARA showing potential for an 840% increase and TKNO for a 159% increase, driven by promising clinical developments and market positioning.
Are There Significant Growth Opportunities for Alpha Teknova (TKNO)?
Prosper Stars & Stripes Fund Performance
- Second Quarter 2025 Returns: Prosper Stars & Stripes reported a net return of +9.6% for Q2 2025, underperforming the Russell 2000 Index, which had a total return of +8.5%, and the HFRX Equity Hedge Index, which returned +5.0%.
- Year-to-Date Performance: For the first half of 2025, the fund's net return was (0.8%), compared to (1.8%) for the Russell and +5.9% for the HFRI.
Portfolio Highlights
- US Equities Recovery: The second quarter saw a reversal in US equities, recovering from declines in Q1 2025.
- Top Holdings: The fund's investor letter emphasized its top five holdings, including Alpha Teknova, Inc. (NASDAQ: TKNO).
Alpha Teknova, Inc. Insights
- Company Overview: Alpha Teknova specializes in producing critical reagents for the life sciences sector, focusing on drug development and commercialization.
- Stock Performance: As of August 29, 2025, Alpha Teknova's stock closed at $4.32, with a market cap of $231.186 million. The stock had a one-month return of 1.89% but a 52-week decline of 12.55%.
- Investment Position: Prosper Stars & Stripes initiated a long position in Alpha Teknova, citing significant investments that position the company for growth. They believe the stock could potentially double based on peer valuation levels of 8-10x sales.
Hedge Fund Interest and Revenue
- Hedge Fund Holdings: At the end of Q2 2025, 11 hedge funds held shares of Alpha Teknova, down from 15 in the previous quarter.
- Financial Performance: Alpha Teknova reported Q2 2025 revenue of $10.3 million, a 7% increase from $9.6 million in Q2 2024.
Comparative Investment Outlook
- Investment Potential: While acknowledging Alpha Teknova's potential, the fund suggests that certain AI stocks may offer better upside with less risk.
Additional Resources
- Further Reading: The article encourages readers to explore more on hedge fund investor letters and insights on stock performance.
Alpha Teknova (TKNO) Q2 Revenue Jumps 7%
Earnings Performance: Alpha Teknova reported a narrower net loss of $0.07 per share for Q2 2025, beating expectations of a $0.10 loss, while revenue grew by 7% year-over-year to $10.3 million, surpassing analyst projections.
Operational Highlights: The company achieved significant gross margin expansion to 38.7% due to improved manufacturing efficiency and cost control, while also launching an expanded partnership with Pluristics for cryopreservation products, although financial impacts from this collaboration are expected to materialize in the future.
Teknova Reports First Quarter 2025 Financial Results
Financial Performance: Alpha Teknova reported a total revenue of $9.8 million for the first quarter of 2025, marking a 5% increase from the previous year, and reaffirmed its revenue guidance for the year at $39-42 million.
Product Development: The company introduced the PluriFreeze™ cryopreservation system in collaboration with Pluristyx, Inc., enhancing its cell therapy product portfolio as it continues to focus on organic growth amidst market uncertainties.
Alpha Teknova (TKNO) Third Quarter 2025 Earnings Call Transcript
- Author's Perspective: The views and opinions presented are solely those of the author.
- No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
IMRX Rises on Pancreatic Cancer Findings, PEPG Achieves DM1 Splicing Correction Milestone, CLPT Under Observation
Biotech Stock Performance: Several biotech stocks, including PepGen and Immuneering, experienced significant gains due to positive clinical trial results, with PepGen's stock soaring 36% during regular trading and an additional 134% in after-hours trading following promising data for its myotonic dystrophy treatment.
Clinical Trial Updates: Immuneering reported an impressive overall survival rate of 86% in its pancreatic cancer trial, while other companies like Clearmind Medicine and Jasper Therapeutics also saw stock increases based on ongoing clinical evaluations and positive preliminary results.
Market Developments: ClearPoint Neuro's stock surged over 58% after receiving FDA clearance for its laser therapy system, expanding its market potential, while Neuphoria Therapeutics anticipates topline results from its social anxiety disorder trial in early Q4 2025.
Investor Interest: The overall investor interest in biotech stocks is reflected in the significant price movements of various companies, driven by clinical trial advancements and strategic opportunities, indicating a robust market for biotech innovations.
Experts Forecast Potential 840% Surge for These 2 'Strong Buy' Penny Stocks
Penny Stocks vs. Mega-Cap Stocks: While large companies like Nvidia dominate the stock market, penny stocks (priced below $5) offer significant growth potential, with the possibility of triple-digit percentage gains, though investors must be cautious due to inherent risks.
Highlighted Penny Stocks: Two penny stocks, Protara Therapeutics (TARA) and Alpha Teknova (TKNO), have received strong buy ratings from analysts, with TARA showing potential for an 840% increase and TKNO for a 159% increase, driven by promising clinical developments and market positioning.
Are There Significant Growth Opportunities for Alpha Teknova (TKNO)?
Prosper Stars & Stripes Fund Performance
- Second Quarter 2025 Returns: Prosper Stars & Stripes reported a net return of +9.6% for Q2 2025, underperforming the Russell 2000 Index, which had a total return of +8.5%, and the HFRX Equity Hedge Index, which returned +5.0%.
- Year-to-Date Performance: For the first half of 2025, the fund's net return was (0.8%), compared to (1.8%) for the Russell and +5.9% for the HFRI.
Portfolio Highlights
- US Equities Recovery: The second quarter saw a reversal in US equities, recovering from declines in Q1 2025.
- Top Holdings: The fund's investor letter emphasized its top five holdings, including Alpha Teknova, Inc. (NASDAQ: TKNO).
Alpha Teknova, Inc. Insights
- Company Overview: Alpha Teknova specializes in producing critical reagents for the life sciences sector, focusing on drug development and commercialization.
- Stock Performance: As of August 29, 2025, Alpha Teknova's stock closed at $4.32, with a market cap of $231.186 million. The stock had a one-month return of 1.89% but a 52-week decline of 12.55%.
- Investment Position: Prosper Stars & Stripes initiated a long position in Alpha Teknova, citing significant investments that position the company for growth. They believe the stock could potentially double based on peer valuation levels of 8-10x sales.
Hedge Fund Interest and Revenue
- Hedge Fund Holdings: At the end of Q2 2025, 11 hedge funds held shares of Alpha Teknova, down from 15 in the previous quarter.
- Financial Performance: Alpha Teknova reported Q2 2025 revenue of $10.3 million, a 7% increase from $9.6 million in Q2 2024.
Comparative Investment Outlook
- Investment Potential: While acknowledging Alpha Teknova's potential, the fund suggests that certain AI stocks may offer better upside with less risk.
Additional Resources
- Further Reading: The article encourages readers to explore more on hedge fund investor letters and insights on stock performance.
Alpha Teknova (TKNO) Q2 Revenue Jumps 7%
Earnings Performance: Alpha Teknova reported a narrower net loss of $0.07 per share for Q2 2025, beating expectations of a $0.10 loss, while revenue grew by 7% year-over-year to $10.3 million, surpassing analyst projections.
Operational Highlights: The company achieved significant gross margin expansion to 38.7% due to improved manufacturing efficiency and cost control, while also launching an expanded partnership with Pluristics for cryopreservation products, although financial impacts from this collaboration are expected to materialize in the future.
Teknova Reports First Quarter 2025 Financial Results
Financial Performance: Alpha Teknova reported a total revenue of $9.8 million for the first quarter of 2025, marking a 5% increase from the previous year, and reaffirmed its revenue guidance for the year at $39-42 million.
Product Development: The company introduced the PluriFreeze™ cryopreservation system in collaboration with Pluristyx, Inc., enhancing its cell therapy product portfolio as it continues to focus on organic growth amidst market uncertainties.
